A drug company in Belfast is working with Queen’s University on developing molecules which could help neutralise the virus which causes Covid-19.
Fusion Antibodies has announced it’s now part of the Northern Ireland Coronavirus Antibody Development Alliance, set up to help in the global fight against the coronavirus pandemic.
The business specialises in pre-clinical antibody discovery, engineering and supply.
Fusion Antibodies is now working with Professor Ultan Power, of the Wellcome-Wolfson Institute of Experimental Medicine, Professor Chris Scott, in The Patrick G Johnston Centre for Cancer Research, and Dr Fuquan Lui, in the School of Biological Sciences, to prepare antibodies that will potentially neutralise the virus.
Fusion Antibodies wil work on the development of key anti-body related reagents.
Chief executive Paul Kerr said: “We are delighted to be able assist in the global battle against coronavirus. In the first instance we’ll work with Queen’s University Belfast to use our expertise in the development of any key reagents.”
Professor Chris Scott, director of the Patrick G Johnston Cancer Centre, Queen’s University Belfast, said: “By bringing together diverse researchers from virology, biological sciences and cancer research we are rapidly contributing to the development of new reagents that could not only neutralize the virus, but also aid diagnostic efforts; both of which are needed to inform decisions on lifting the current lockdown. We are delighted to initiate this alliance with Fusion Antibodies and to direct our research capabilities towards tackling this global pandemic.”